Methods	Six-week randomised, double-blind study.
Participants	In- and out-patients fulfilling DSM-III-R criteria for major depression without psychotic features, with a score of at least 17 on the HDRS-17. Age range: 18-70 years. Exclusion criteria: suicidal intent, any other psychiatric illness, severe organic disease, alcoholism and drug abuse, use of MAOI in the preceeding 2 week, use of an antudepressant drug in the previous 4 days, or any investigational drug in the preceeding 4 weeks, patients who ever received fluoxetine or moclobemide
Interventions	Fluoxetine: 25 participants. Moclobemide: 24 participants. Fluoxetine dose range: 20-40 mg/day. Moclobemide dose range: 300-600 mg/day. Only lithium and bromazepam were allowed.
Outcomes	Primary outcomes: final score of less than 10 or a decrease of at least 50% from baseline on the Hamilton Rating Scale for Depression (HDRS-17), CGI
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear